Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy | Zendy

TungHung Su | Zendy; HungChih Yang | Zendy; TaiChung Tseng | Zendy; JyhMing Liou | Zendy; ChenHua Liu | Zendy; ChiLing Chen | Zendy; PeiJer Chen | Zendy; DingShinn Chen | Zendy; ChunJen Liu | Zendy; JiaHorng Kao | Zendy

AI Assistant Blog Pricing

Open Access

Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy

Author(s) -

TungHung Su,

HungChih Yang,

TaiChung Tseng,

JyhMing Liou,

ChenHua Liu,

ChiLing Chen,

PeiJer Chen,

DingShinn Chen,

ChunJen Liu,

JiaHorng Kao

Publication year - 2017

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jix690

Subject(s) - entecavir , tenofovir , medicine , antiretroviral therapy , oncology , virology , human immunodeficiency virus (hiv) , hepatitis b virus , lamivudine , viral load , virus

We investigated the patterns and predictors for virological relapse (VR), clinical relapse (CR), and sustained clinical response (SCR) and the outcomes of retreatment after nucleos(t)ide analogue (NUC) therapy discontinuation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog